. 2006 Apr 18;12(Suppl 3):42–54. doi: 10.1111/j.1469-0691.2006.01396.x

Table 1.

Double blind, randomized clinical trials, where FQ are compared against other antibiotics for the treatment of patients with acute exacerbations of chronic bronchitis

Author/year	Antibiotics	Dose (mg/h)	Days	total number of patients assessed	mean age (years)	type of exacerbation ^§	% with favorable evolution (at 7–21 days)	bacteriologic eradication cases/total (%)
Chodosh¹²¹ 1998	Ciprofloxacin	500/12	14	99	61	I‐II‐III	90	86/95 (91) **
Chodosh¹²¹ 1998	Clarithromycin	500/12	14	91	62		82	67/87 (77)
Chodosh¹²² 1998	Ciprofloxacin	500/12	14	103	57	nd	93	89/93 (96) **
Chodosh¹²² 1998	Cefuroxime	500/12	14	105	58		90	80/97 (82)
Grassi¹²³ 2002	Ciprofloxacin	500/12	10	110	65	II	85 ^#	46/50 (92)
Grassi¹²³ 2002	Pruliflofloxacin	600/12	10	112	67		85	47/53 (89)
Langan¹²⁴ 1999	Grepafloxacin	400/24	5	156	57	II	72	58/89 (65)
	Grepafloxacin	400/24	10	157	56		81	58/86 (67)
	Clarithromycin	250/12	10	160	57		73	62/104 (60)
Masterton¹²⁵ 2001	Levofloxacin	500/24	5	238	61	II	83	92/112 (82))
Masterton¹²⁵ 2001	Levofloxacin	500/24	7	244	59		85	84/101 (83
Amsden¹²⁶ 2003	Azythromycin	500‐250/24	5	108	58	I‐II	82	22/23 (96)
Amsden¹²⁶ 2003	Levofloxacin	500/24	7	104	59	I‐II	86	17/20 (85)
Wilson¹²⁷ 2002	Gemifloxacin	320/24	5	351	59	I	85	39/45 (87)
Wilson¹²⁷ 2002	Clarithromycin	500/12	7	358	58		85	38/52 (73)
Sethi¹²⁸ 2004	Gemifloxacin	320/24	5	170	62	I‐II	88	(78)
Sethi¹²⁸ 2004	Levofloxacin	500/24	7	164	63		85	(86)
Gotfried¹²⁹ 2001	Gatifloxacin	400/24	5	174	48	I‐II	89	85/87 (98)
	Gatifloxacin	400/24	7	175	49		88	75/80 (94)
	Clarithromycin	500/12	10	178	48		89	87/89 (98)
Soler¹³⁰ 2003	Gatifloxacin	200/24	5	138	62	II	82	55/65 (86)
	Gatifloxacin	400/24	5	136	60		81	47/61 (77)
	Amoxy‐Clav.	500/8	10	126	62		82	51/67 (76)
Wilson¹³¹ 1999	Moxifloxacin	400/12	5	322	60	I‐II	89	89/115 (77) **
Wilson¹³¹ 1999	Clarithromycin	500/12	7	327	60		88	71/114 (62)
Chodosh¹³²2000	Moxifloxacin	400/24	5	143	57	I‐II	89	127/143 (89)
	Moxifloxacin	400/24	10	148	55		91	135/148 (91)
	Clarithromycin	500/12	10	129	54		91	110/129 (85)
DeAbate¹³³ 2000	Moxifloxacin	400/24	5	221	54	I‐II	88	105/119 (88)
DeAbate¹³³ 2000	Azythromycin	500‐250	5	243	54		88	102/118 (86)
Wilson¹³⁴ 2004	Moxifloxacin	400/24	5	274	64	I	70	62/71 (91) **
	Other Atb:
	Amoxycillin	500/8
	Clarithromycin	500/12	7	298	63		62	66/79 (81)
	Cefuroxime	250/12

^{^*}

assessment performed at days 2‐7 after treatment

^{^†}

assessment performed at day 2 after treatment

^{^§}

Type of exacerbation following Anthonisen's classification⁹¹

^{^**}

p < 0.05